Overview
A J-code is a HCPCS Level II procedure code beginning with the letter J that identifies a specific physician-administered drug or biological product. J-codes are the primary billing codes for injectable and infused drugs delivered in outpatient settings — infusion centers, physician offices, hospital outpatient departments, and ambulatory surgery centers. Unlike the NDC (National Drug Code), which identifies a specific manufacturer's package of a drug at a specific strength and package size, the J-code identifies the drug and dosing unit for reimbursement purposes across all manufacturers.
J-codes span therapeutic categories: oncology drugs (J9000 series), biologicals (J1610–J3490 range), immunologic agents, cardiovascular drugs, antimicrobial agents, vitamins and minerals, and many others. Each J-code has a specific dosing unit — for example, J9035 is "bevacizumab injection, 10 mg." A 400 mg dose is billed as J9035 × 40 units. This dose-unit mechanism allows precise billing regardless of which NDC (manufacturer package) was dispensed.
Medicare reimburses J-codes under two main frameworks. For drugs covered under Medicare Part B, reimbursement is typically Average Sales Price (ASP) +6% for non-340B purchases, with specific adjustments for shortage drugs and certain categories. For drugs covered under Medicare Advantage, payment follows the plan's contracted methodology, often referencing ASP +6% with plan-specific adjustments. Medicaid pays J-codes through state-specific fee schedules or AAC (Average Acquisition Cost)-based methodologies.
For RCM, J-code billing involves specific workflow considerations. (1) Drug identification must map the dispensed product (NDC-level) to the correct J-code for billing. Wasted doses and multi-dose-vial tracking require careful unit calculation. (2) J-codes must appear on the claim with the correct unit count reflecting the administered dose. (3) Administration CPT codes (96365 infusion, 96374 IV push, 96372 IM injection) are billed separately from the J-code drug cost. (4) 340B-purchased drugs require JG or TB modifier (see 340B Drug Pricing).
Specialty drug billing is a major J-code area. Oncology, immunology (rheumatoid arthritis biologics), ophthalmology (anti-VEGF injectables), and infusible biologics generate very high dollar values per administration — single doses can exceed $10,000. Accurate J-code billing, precise unit calculation, and correct ASP-based reimbursement matter enormously for specialty practice economics.
Waste and refills complicate J-code billing. A single-dose vial labeled 100 mg used for an 80 mg prescription generates 20 mg of waste; the JW (discarded drug) modifier tracks the wasted portion for appropriate reimbursement or documentation. Effective 2023, Medicare requires JW reporting for single-dose vial wastage with specific documentation standards.
J-codes are updated quarterly through the HCPCS Level II code set. New codes reflect newly approved drugs; temporary codes (J3490 for unclassified drugs, C-codes for transitional hospital outpatient billing) accommodate drugs awaiting permanent HCPCS assignment. Billing teams must track HCPCS updates, transition claims to new codes promptly, and maintain cross-references between J-codes, NDCs, and drug inventory.
Industry benchmark
CMS HCPCS Level II code list. Medicare Claims Processing Manual Chapter 17 (Drugs and Biologicals). Medicare Part B ASP pricing files.
Worked example
A patient receives pembrolizumab 200 mg infusion for melanoma. J-code J9271 = "pembrolizumab injection, 1 mg." Billing: J9271 × 200 units, with 96413 or 96365 for the infusion administration. Medicare Part B ASP for pembrolizumab (hypothetical) $50/mg +6%: reimbursement approximately $10,600 for the drug plus separate administration fee. JW modifier applied to any documented wastage from a single-dose vial. 340B-covered entity adds JG modifier; non-340B does not.
Frequently asked questions — J-Code (HCPCS Level II Drug Code)
What is the difference between a J-code and an NDC?
A J-code is a HCPCS Level II billing code for a drug at a specific dosing unit (e.g., J9035 = bevacizumab 10 mg). An NDC is a manufacturer-specific product identifier for a specific package of drug at a specific strength. J-codes are used for billing; NDCs for inventory, dispensing, and sometimes required on claims as secondary identifiers.
How is Medicare Part B J-code payment calculated?
Typically Average Sales Price (ASP) +6% for non-340B purchases. CMS publishes quarterly ASP pricing files for all J-codes. 340B-purchased drugs continue to receive ASP +6% reimbursement but the covered entity captures spread between low 340B acquisition cost and Medicare payment.
What is the JW modifier?
JW identifies discarded drug from a single-dose vial — the portion of a dose that was not administered (waste). Medicare requires JW reporting for documentation of single-dose vial wastage with specific quantity and documentation standards as of 2023.
How are J-codes updated?
HCPCS Level II is updated quarterly. New drugs receive new J-codes as they are approved; temporary codes (J3490 unclassified, C-codes for transitional hospital outpatient) handle drugs awaiting permanent assignment. Billing systems must track HCPCS updates to avoid using expired or replaced codes.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.